Cilag International has given Basilea Pharmaceutica a notice of termination of the worldwide license, development and co-promotion agreement between the parties. The compound, including pending applications and in-market products, will be transitioned back to Basilea under the terms of the license agreement.
Zeftera (ceftobiprole medocaril for injection, henceforth known as ceftobiprole) is a cephalosporin antibiotic indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms in patients 18 years of age and older.
Janssen-Cilag International and Cilag GmbH International are Johnson & Johnson companies.